title: Management of fibromyalgia syndrome--an interdisciplinary evidence-based guideline.
abstract: The prevalence of fibromyalgia syndrome (FMS) of 1-2% in the general population associated with high disease-related costs and the conflicting data on treatment effectiveness had led to the development of evidence-based guidelines designed to provide patients and physicians guidance in selecting among the alternatives. Until now no evidence-based interdisciplinary (including patients) guideline for the management of FMS was available in Europe. Therefore a guideline for the management of fibromyalgia syndrome (FMS) was developed by 13 German medical and psychological associations and two patient self-help organisations. The task was coordinated by two German scientific umbrella organisations, the Association of the Scientific Medical Societies in Germany AWMF and the German Interdisciplinary Association of Pain Therapy DIVS. A systematic search of the literature including all controlled studies, systematic reviews and meta-analyses of pharmacological and non-pharmacological treatments of FMS was performed in the Cochrane Library (1993-12/2006), Medline (1980-12/2006), PsychInfo (1966-12/2006) and Scopus (1980-12/ 2006). Levels of evidence were assigned according to the classification system of the Oxford-Centre for Evidence Based Medicine. Grading of the strengths of recommendations was done according to the German program for disease management guidelines. Standardized procedures were used to reach a consensus on recommendations. The guideline was reviewed and finally approved by the boards of the societies involved and published online by the AWMF on april 25, 2008: http://www.uni-duesseldorf.de/AWMF/ll/041-004.htm. A short version of the guideline for patients is available as well: http://www.uni-duesseldorf.de/AWMF/ll/041-004p.htm. The following procedures in the management of fms were strongly recommended: information on diagnosis and therapeutic options and patient-centered communication, aerobic exercise, cognitive and operant behavioural therapy, multicomponent treatment and amitriptyline. Based on expert opinion, a stepwise FMS-management was proposed. Step 1 comprises confirming the diagnosis and patient education and treatment of physical or mental comorbidities or aerobic exercise or cognitive behavioural therapy or amitriptyline. Step 2 includes multicomponent treatment. Step 3 comprises no further treatment or self-management (aerobic exercise, stress management) and/or booster multicomponent therapy and/or pharmacological therapy (duloxetine or fluoxetine or paroxetine or pregabalin or tramadol/aminoacetophen) and/or psychotherapy (hypnotherapy or written emotional disclosure) and/or physical therapy (balneotherapy or whole body heat therapy) and/or complementary therapies (homeopathy or vegetarian diet). The choice of treatment options should be based on informed decision-making and respect of the patients' preferences.
authors.affiliation: Department of Internal Medicine I, Klinikum Saarbrücken, Germany. whaeuser@klinikum-saarbruecken.de
authors.forename: Winfried
authors.initials: W
authors.lastname: Häuser
authors.forename: Bernhard
authors.initials: B
authors.lastname: Arnold
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Eich
authors.forename: Eva
authors.initials: E
authors.lastname: Felde
authors.forename: Christl
authors.initials: C
authors.lastname: Flügge
authors.forename: Peter
authors.initials: P
authors.lastname: Henningsen
authors.forename: Markus
authors.initials: M
authors.lastname: Herrmann
authors.forename: Volker
authors.initials: V
authors.lastname: Köllner
authors.forename: Edeltraud
authors.initials: E
authors.lastname: Kühn
authors.forename: Detlev
authors.initials: D
authors.lastname: Nutzinger
authors.forename: Martin
authors.initials: M
authors.lastname: Offenbächer
authors.forename: Marcus
authors.initials: M
authors.lastname: Schiltenwolf
authors.forename: Claudia
authors.initials: C
authors.lastname: Sommer
authors.forename: Kati
authors.initials: K
authors.lastname: Thieme
authors.forename: Ina
authors.initials: I
authors.lastname: Kopp
references.citation: J Rheumatol. 1999 Apr;26(4):885-9
references.pmid: 10229411
references.citation: Schmerz. 2008 Jun;22(3):303-12
references.pmid: 18449569
references.citation: Schmerz. 2008 Jun;22(3):324-33
references.pmid: 18463899
references.citation: Arthritis Rheum. 1990 Feb;33(2):160-72
references.pmid: 2306288
references.citation: Disabil Rehabil. 2005 Jun 17;27(12):685-94
references.pmid: 16012061
references.citation: Schmerz. 2008 Jun;22(3):244-54
references.pmid: 18458960
references.citation: Arthritis Rheum. 1997 Sep;40(9):1560-70
references.pmid: 9324009
references.citation: Schmerz. 2008 Jun;22(3):334-8
references.pmid: 18463898
references.citation: Schmerz. 2008 Jun;22(3):283-94
references.pmid: 18478270
references.citation: Med Klin (Munich). 2006 Oct 15;101(10):840-5
references.pmid: 17039328
references.citation: Expert Opin Pharmacother. 2006 Jun;7(8):1027-39
references.pmid: 16722813
references.citation: J Rheumatol. 2004 Jul;31(7):1391-8
references.pmid: 15229962
references.citation: Schmerz. 2000 Apr;14(2):77-83
references.pmid: 12800043
references.citation: Schmerz. 2008 Jun;22(3):295-302
references.pmid: 18458959
references.citation: Ann Rheum Dis. 2008 Apr;67(4):536-41
references.pmid: 17644548
references.citation: Rheumatology (Oxford). 2007 May;46(5):801-4
references.pmid: 17189243
references.citation: BMC Musculoskelet Disord. 2007 Mar 09;8:27
references.pmid: 17349056
references.citation: Acta Neurol Belg. 2006 Dec;106(4):149-56
references.pmid: 17323832
references.citation: Schmerz. 2008 Jun;22(3):313-23
references.pmid: 18458958
references.citation: Psychosom Med. 2003 Jul-Aug;65(4):528-33
references.pmid: 12883101